# An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury

> **NCT01814982** · PHASE2 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 7 (actual)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **DRUG:** JNJ-17299425

## Key facts

- **NCT ID:** NCT01814982
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** reprioritization of company activities
- **Last updated:** 2013-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01814982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01814982, "An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01814982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*